近日,国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗(美佑恒)上市,用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者,为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物,由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成,通过抑制微管生成、阻断有丝分裂并诱导凋亡,还具ADCC作用,体外可杀伤多种EGFR表达水平的肿瘤细胞,抑制...
Source Link近日,国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗(美佑恒)上市,用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者,为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物,由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成,通过抑制微管生成、阻断有丝分裂并诱导凋亡,还具ADCC作用,体外可杀伤多种EGFR表达水平的肿瘤细胞,抑制...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.